Literature DB >> 18694475

Early pulse pressure and low-grade proteinuria as independent long-term risk factors for new-onset diabetes mellitus after kidney transplantation.

M Roland1, P Gatault, A Al-Najjar, C Doute, C Barbet, V Chatelet, I Laouad, J-F Marlière, H Nivet, M Büchler, Y Lebranchu, J-M Halimi.   

Abstract

Risk factors for new-onset diabetes after transplantation (NODAT) need to be assessed in large cohorts. We retrospectively evaluated the impact of early (3 and 6 months after transplantation) proteinuria, urinary albumin excretion (UAE) and arterial pressure on NODAT in 828 Caucasian renal transplant recipients (median follow-up: 5.3 years; 5832 patient-years). The 10- and 20-year incidence of NODAT was 15.0% and 22.0%, respectively. Low-grade (<1 g/day) (HR: 2.04 [1.25-3.33], p = 0.0042) and very low-grade (<0.3 g/day) (HR: 2.21 [1.32-3.70], p = 0.0025) proteinuria were independent risk factors for NODAT. There was a dose-dependent relationship across UAE categories (increasing risk from normoalbuminuria to macroalbuminuria) with NODAT. Tacrolimus, sirolimus and beta-blockers (HR: 1.86 [1.07-3.22], p = 0.0277) were significantly associated with NODAT even after multiple adjustments, but not diuretics, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. Systolic arterial pressure (HR per 10 mmHg: 1.16 [1.03-1.29], p = 0.0126) and pulse pressure (HR: 1.26 [1.12-1.43], p = 0.0002) were associated with NODAT. Only pulse pressure remained significant after adjustments. Patients at highest risks had early proteinuria and pulse pressure >60 mmHg. Early low-grade proteinuria and pulse pressure (in addition to beta-blockers) constitute independent risk factors for NODAT; they may be markers of the metabolic syndrome and/or vascular damage in renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18694475     DOI: 10.1111/j.1600-6143.2008.02308.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

1.  TCF7L2 polymorphism associates with new-onset diabetes after transplantation.

Authors:  Lidia Ghisdal; Christophe Baron; Yannick Le Meur; Arnaud Lionet; Jean-Michel Halimi; Jean-Philippe Rerolle; François Glowacki; Yvon Lebranchu; Mireille Drouet; Christian Noël; Hakim El Housni; Pascale Cochaux; Karl Martin Wissing; Daniel Abramowicz; Marc Abramowicz
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

2.  New onset diabetes after transplantation (NODAT): an overview.

Authors:  Phuong-Thu T Pham; Phuong-Mai T Pham; Son V Pham; Phuong-Anh T Pham; Phuong-Chi T Pham
Journal:  Diabetes Metab Syndr Obes       Date:  2011-05-09       Impact factor: 3.168

Review 3.  Diabetes and Cardiovascular Risk in Renal Transplant Patients.

Authors:  Jacek Rysz; Beata Franczyk; Maciej Radek; Aleksandra Ciałkowska-Rysz; Anna Gluba-Brzózka
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

4.  Risk factors for new-onset diabetes mellitus after kidney transplantation: A systematic review and meta-analysis.

Authors:  Mancheng Xia; Haosen Yang; Xunan Tong; Hongjie Xie; Fan Cui; Weibing Shuang
Journal:  J Diabetes Investig       Date:  2020-07-12       Impact factor: 4.232

5.  Metabolic syndrome in hemodialysis patients as a risk factor for new-onset diabetes mellitus after renal transplant: a prospective observational study.

Authors:  Josep Bonet; Albert Martinez-Castelao; Beatriz Bayés
Journal:  Diabetes Metab Syndr Obes       Date:  2013-09-18       Impact factor: 3.168

6.  Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters.

Authors:  Florian Terrec; Thomas Jouve; Hamza Naciri-Bennani; Pierre-Yves Benhamou; Paolo Malvezzi; Benedicte Janbon; Diane Giovannini; Lionel Rostaing; Johan Noble
Journal:  Transplant Direct       Date:  2019-12-24

Review 7.  Chronic Kidney Allograft Disease: New Concepts and Opportunities.

Authors:  Sergi Codina; Anna Manonelles; Maria Tormo; Anna Sola; Josep M Cruzado
Journal:  Front Med (Lausanne)       Date:  2021-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.